アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Human placental insulin receptor.
Abcam is committed to meeting high standards of ethical manufacturing and has decided to discontinue this product by June 2019 as it has been generated by the ascites method. We are sorry for any inconvenience this may cause.
Our Abpromise guarantee covers the use of ab983 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 1µg for 106 cells.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 18411068|
|Blocking||Use at an assay dependent concentration. Dilute in PBS or medium which is identical to that used in the assay system.|
|Functional Studies||Use at an assay dependent concentration. Inhibition of insulin binding: IM-9 lymphocytes = 35%, Adipocytes = 90% Concentration for half maximal effect: Inhibition of insulin binding = 0.2nM, Stimulation of lipogenesis = 0.3nM. This antibody has insulin-like biological activity and therefore activates the receptor kinase.|
|IP||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration.|
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"